- Published at
- by manilatimes.net
mixed
mixed
News for Yuhan Corporation (000105.KS)
- Published at
- by gurufocus.com
mixedmixedRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
PR NewswireRARITAN, N.J., Jan. 7, 2025 Median overall survival improvement expected to exceed one yearFirst and only regimen with a survival benefit over c- Published at
- by manilatimes.net
positivepositiveJ INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy
- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a pioneering collaboration in precision oncology.- Published at
- by globenewswire.com
neutralneutralUrticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic...- Published at
- by globenewswire.com
mixedmixedRYBREVANT®▼ (amivantamab) plus Chemotherapie zeigt positiven Trend beim Gesamtüberleben im Vergleich zur Chemotherapie bei Patienten mit vorbehandeltem EGFR-mutiertem Lungenkrebs
Die Ergebnisse nach dem Fortschreiten der Krankheit zeigten eine signifikante und anhaltende Verbesserung für amivantamab plus Chemotherapie im Vergleich...- Published at
- by investing.com
positivepositiveRYBREVANT ® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer By Investing.com
RYBREVANT ® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer- Published at
- by globenewswire.com
mixedmixedRYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM ,...- Published at
- by globenewswire.com
mixedmixedRYBREVANT®▼ (Amivantamab) plus Lazertinib zeigen einen starken positiven Trend beim Gesamtüberleben im Vergleich zu Osimertinib bei EGFR-mutiertem fortgeschrittenem Lungenkrebs
Neue Langzeitdaten aus der MARIPOSA-Studie bestätigen die überlegenen Ergebnisse der lazertinib-plus-lazertinib-Therapie im Vergleich zur...- Published at
- by globenewswire.com
mixedmixedRYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as...- Published at
- by investing.com
positivepositiveRYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer By Investing.com
RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer- Published at
- by globenewswire.com
mixedmixedTuberculosis Pipeline Landscape Analysis of 38+ Companies by DelveInsight
Tuberculosis (TB) is a chronic condition and has become a global disease burden. Advanced technologies as well as the introduction of novel therapies are...- Published at
- by business-standard.com
positivepositiveGlenmark Pharma inks exclusive licensing agreement with Lotus International
Read more about Glenmark Pharma inks exclusive licensing agreement with Lotus International on Business Standard. Glenmark Pharmaceuticals Ltd on Thursday said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd- Published at
- by moneycontrol.com
positivepositiveGlenmark Pharma inks exclusive licensing agreement with Lotus International
Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for manufacturing and supply of Ryaltris.